When was avengebio founded?

avengebio was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is avengebio located?

avengebio is headquartered in Cambridge, United States. It is registered at 22 Strathmore Rd, STE 241 Natick, MA 01760.

Who is the current CEO of avengebio?

Michael Heffernan of avengebio.

How many employees does avengebio have?

As of Aug 31, 2026, the latest employee count at avengebio is 3.

Is avengebio a funded company?

avengebio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jan 05, 2022.

When was the latest funding round of avengebio?

avengebio's latest funding was a $***** Series A round on Jan 05, 2022, with participation from 5 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.48B in funding in 2026 to date.

Where does avengebio rank among its competitors?

avengebio ranks 952nd amongst 3417 active competitors, of which 1140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of avengebio?

avengebio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

avengebio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of immunotherapies for the treatment of cancer. The company is developing a proprietary, allogeneic LOCOcyte platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for the eradication of solid tumors. The company has a pipeline of drugs for metastatic peritoneal cancer, breast, lung, and ovarian cancer.

Website: avengebio.com
Social
Email ID: *****@avengebio.com
Registered Address: 22 Strathmore Rd, STE 241 Natick, MA 01760

Key Metrics

Founded Year

2019

Location

Cambridge, United States

Stage

Series A

Total Funding

$45M in 1 round

Latest Funding Round

Series A, Jan 05, 2022, $*****

Investors

CAM Capital & 4 more

Ranked

952^nd among 3417 active competitors

Employee Count

3 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3065 more

View avengebio's full profile

avengebio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AVENGE BIO, INC. CIN: 83-3772333 , United States, Active	Feb 27, 2019	-	8 (As on Dec 31, 2021)	-

avengebio has raised a total funding of $45M over 1 round. Its latest funding round was a Series A round on Jan 05, 2022 for $*****. 5 investors participated in its latest round. avengebio has 5 institutional investors.

Here is the list of recent funding rounds of avengebio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 05, 2022	2730460	Series A	6978168	7819082	9002803	5678741

Access funding benchmarks and valuations. Sign up today!

View details of avengebio's funding rounds and investors

The founders of avengebio are Paul Wotton and Michael Heffernan. Michael Heffernan is the CEO of avengebio.

Here are the details of avengebio's key team members:

Paul Wotton: Co-Founder of avengebio. They serve on the board of 1 company.
Michael Heffernan: Co-Founder & CEO of avengebio.

View details of avengebio's Founder profiles and Board Members

avengebio's employee count trend

avengebio has 3 employees as of Aug 26. Here is avengebio's employee count trend over the years:

Uncover avengebio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of avengebio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of avengebio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
952nd	avengebio 2019, Cambridge (United States), Series A	Developer of immunotherapies for the treatment of cancer	$45M	Longitude Capital, CAM Capital & 3 others	42/100